'We want to be everywhere.' Mission Bio raises $70M behind resistance-hunting sequencing platform
Charlie Silver wants to look really, really closely at a lot of your cells. And he just got a lot of money to do so.
Silver’s startup, Mission Bio, raised $70 million in a Series C round Thursday led by Novo Holdings. The money, which brings Mission Bio to $120 million raised since its 2012 founding, will be used to advance the single-cell sequencing platform they built to detect early response or resistance to new cancer therapies.